Ligand Buys Programs From Selexis SA

San Diego-based Ligand Pharmaceuticals announced this morning that it has acquired more than 15 different programs from Selexis SA, for $4M in cash. Ligand--which develops a range of pharmaceuticals--said that it acquired a number of programs in various stages of development, ranging from preclinical through Phase 3 studies. Ligand said each of the programs is already fully funded by a development partner.